TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28717702
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine once per day
Study: 18645193
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1,000 mg)
Study: 15909176
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) - 3000 shocks of 0.20 mJ/mm(2)
Study: 12877888
Drug: Aprotinin (APRO)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (APRO) at a low dose of 2 Mio KIU in the priming volume
Study: 10360185
Drug: Multidrug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug therapy with a protease inhibitor
Study: 10360185
Drug: No multidrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No multidrug therapy with a protease inhibitor
Study: 7740525
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs (3.4 g eicosapentaenoic and docosahexaenoic acids per day) for six months
Study: 2139385
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg/die)
Study: 7234470
Drug: brief care
Approvals — FDA: no, EMA: no, PMDA: no
Description: brief care (acute treatment aimed at effecting the patient's discharge after about a week)
Study: 29803597
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser vaporization (L group)
Study: 22136068
Drug: NVP XR
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP XR 400 mg once daily
Study: 22136068
Drug: NVP IR
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP IR 200 mg twice daily
Study: 17966175
Drug: Dapsone gel
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone gel 5% applied twice daily for up to 12 months
Study: 17966175
Drug: Dapsone gel
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone gel 5%
Study: 10334524
Drug: Single-agent drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent drugs (trimetrexate, melphalan, amonafide, carboplatin, or elsamitrucin) followed by CAF
Study: 10334524
Drug: Single-agent drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent drugs followed by CAF
Study: 8305994
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive drug therapy
Study: 8305994
Drug: Moderate antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate antihypertensive drug therapy
Study: 8960857
Drug: Nisoldipine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (calcium channel blocker)
Study: 8960857
Drug: Enalapril (angiotensin‐converting‐enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (angiotensin‐converting‐enzyme inhibitor)
Study: 8960857
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive therapy
Study: 8960857
Drug: Moderate antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate antihypertensive therapy
Study: 19589241
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg/day)
Study: 6761595
Drug: CD combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD combination
Study: 30415307
Drug: Awareness Index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness Index of antibiotic resistance
Study: 30415307
Drug: Antibiotic conservation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic conservation practices
Study: 26691608
Drug: School-based child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based child oral hygiene program
Study: 24067296
Drug: Digoxin 0.125
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.125 mg/day
Study: 24067296
Drug: Digoxin ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin ≥ 0.25 mg/day
Study: 20854139
Drug: Bedtime administration
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime administration of ≥1 hypertension medications
Study: 20854139
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (all medications ingested upon awakening)
Study: 9596232
Drug: Regular alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular alcohol intake (<50 g/d)
Study: 9596232
Drug: Heavy alcohol
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy alcohol consumption (>=100 g/d)
Study: 7508804
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus intravenous infusion of the prostacyclin analogue iloprost for 6 h per day over 14-21 days
Study: 30111378
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative treatment
Study: 7508804
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus intravenous infusion of the prostacyclin analogue iloprost
Study: 3128439
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (3 mg/h)
Study: 720134
Drug: Urea preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea preparations under occlusive dressings
Study: 27356083
Drug: DHA 20
Normalized name: DHA 200 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA 20 mg/kg/d + ARA 40 or 60 mg/kg/d + ARA 120 mg/kg/d
Study: 21584922
Drug: Intensive subcutaneous
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive subcutaneous insulin protocol
Study: 21584922
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with sliding scale insulin
Study: 20215786
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with etoposide, Adriamycin and cisplatin (EAP)
Study: 20215786
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with EAP
Study: 17469888
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment as usual
Study: 15960083
Drug: Tactile signals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tactile signals administered to the treatment group to indicate the arrival and location of interrupting tasks.
Study: 12360175
Drug: Both atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both atorvastatin and fenofibrate
Study: 10432959
Drug: Etidronate 400
Normalized name: etidronate 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate 400 mg per day for 14 days followed by 500 mg calcium carbonate per day for 76 days, repeated for one year
Study: 6936978
Drug: 3 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injections of a tyrosine adsorbed grass pollen vaccine (Pollagen) immediately preseasonal
Study: 6936978
Drug: 5 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 injections of a tyrosine adsorbed grass pollen vaccine (Pollagen)
Study: 6936978
Drug: 18 injections
Normalized name: quaternium-18
DrugBank: Quaternium-18 (DB11305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 injections of a 7 grass pollen extract (semi‐depot, Allpyral)
Study: 6936978
Drug: 3 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injections of a tyrosine adsorbed grass pollen vaccine (Pollagen)
Study: 28624819
Drug: Intravenous cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefazolin 2 g
Study: 24680234
Drug: Brief, 5-session,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief, 5-session, problem-focused couple therapy for depression
Study: 17236918
Drug: Intravenous prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prophylactic antibiotics (penicillin or clindamycin for penicillin-allergic subjects)
Study: 15051598
Drug: 70 g
Normalized name: alcohol .70 g in 1 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 g MCTs (66% 8:0 and 34% 10:0)
Study: 10535880
Drug: Interferon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (3 MU 3 times weekly) for 24 months
Study: 10535880
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of interferon
Study: 7594123
Drug: Cholesterol-lowering diets
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering diets (30%, 26%, 22%, and 18% of energy from fat; 300, 200, 100, and 100 mg cholesterol)
Study: 1099895
Drug: Iron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron treatment
Study: 29334292
Drug: Fascial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascial therapy (3 sessions, 60 min each)
Study: 27194235
Drug: Colonic irrigation
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonic irrigation using the Ashong colonic irrigation apparatus (ACIA), performed twice daily for 6 consecutive days per week for 1-4 weeks.
Study: 22116114
Drug: Higher class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher class pain medication
Study: 20205646
Drug: Cyclooxygenase-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclooxygenase-2 inhibitors
Study: 7606425
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation (IDEOS) containing 500 mg calcium and 400 IU vitamin D3, taken as one tablet twice daily for six months
Study: 7606425
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of 8 drops of vitamin D3 (800 IU/day) and one calcium carbonate 500 mg tablet twice daily for six months
Study: 91886
Drug: Intramuscular iodised
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular iodised oil
Study: 30985694
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral rectus sheath block (RSB) using 40 mL of 0.375% ropivacaine
Study: 30985694
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving RSB using 40 mL of normal saline
Study: 16487501
Drug: PCIA using
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIA using morphine
Study: 12620951
Drug: Remifentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1 micro g x kg(‐1) iv followed by a continuous infusion of 0.2 to 0.5 micro g x kg(‐1) x min(‐1))
Study: 12620951
Drug: Nitroprusside (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside (0.25 micro g x kg(‐1) x min(‐1) iv and alfentanil iv)
Study: 9345173
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with high energy groundnut biscuits (4.3 MJ/day) for about 20 weeks before delivery
Study: 8155388
Drug: Toremifene 60
Normalized name: toremifene 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 60 mg
Study: 8155388
Drug: Toremifene 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 300 mg
Study: 24997863
Drug: Rg3-enriched Korean
Normalized name: Korean ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rg3-enriched Korean red ginseng (400 mg)
Study: 24997863
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (400 mg)
Study: 22081263
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) 500 mcg every 3 weeks (Q3 W) or 2.25 mcg/kg DA weekly (QW) for 15 weeks
Study: 19929694
Drug: Ad5 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5 vaccine alone
Study: 16188181
Drug: KTP 532
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTP 532 nm laser treatment
Study: 12359987
Drug: Combined medication
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medication (Nitrendipine, Atenolol, Captopril)
Study: 7259925
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg/day
Study: 7259925
Drug: Cimetidine 1600
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1600 mg/day
Study: 7259925
Drug: Cimetidine pharmacokinetics
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine pharmacokinetics
Study: 21239090
Drug: High Protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Protein (HP) diet (3.0 g protein/kg BW) for 3 weeks
Study: 21239090
Drug: Usual Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Protein (UP) diet (1.5 g protein/kg BW) for 3 weeks
Study: 15330150
Drug: steroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroids and oral magnesium
Study: 15330150
Drug: steroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroids and placebo
Study: 7740465
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms ethinyloestradiol combination
Study: 7740465
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms ethinyloestradiol combination
Study: 2965633
Drug: ANP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP with background infusion of ANG II
Study: 24131567
Drug: Exposure Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure Group Therapy (EGT)
Study: 17625032
Drug: 5 mW
Normalized name: POLYETHYLOXAZOLINE (200000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mW laser irradiation (650 nm), applied transmeatally for 15 minutes, once daily for a week
Study: 10627439
Drug: Syndecan-1 elevated
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syndecan-1 elevated in patients (median, 643 units/mL)
Study: 10627439
Drug: Syndecan-1 dichotomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syndecan-1 dichotomized by best cutoff (66th percentile, 1170 units/mL)
Study: 2931937
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection sclerotherapy (ST)
Study: 2931937
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (balloon tamponade and/or vasopression infusion)
Study: 29678977
Drug: Dexmedetomidine (sleep-inducing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (sleep-inducing dose)
Study: 24574278
Drug: Xylitol (Xlear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (Xlear Nasal Spray®)
Study: 12185402
Drug: Hydrocortisone 20
Normalized name: hydrocortisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 20 mg administered twice daily for 7 days
Study: 12185402
Drug: TRH administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH administration after L-tryptophan infusion
Study: 8527275
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg p.o. daily for 2 weeks
Study: 8527275
Drug: Isoniazid 300
Normalized name: isoniazid 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 300 mg p.o. daily for 1 week
Study: 2121848
Drug: Prolonged praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged praziquantel courses (initial dose of 40 mg/Kg, followed by 6-monthly full dose)
Study: 2121848
Drug: Prolonged praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged praziquantel courses (initial dose of 40 mg/Kg, followed by 3-monthly half doses)
Study: 2121848
Drug: Prolonged praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged praziquantel courses (initial dose of 40 mg/Kg, followed by monthly half doses)
Study: 2121848
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B complex (placebo)
Study: 23570248
Drug: Clarithromycin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (7.5 mg/kg/dose every 12 hours)
Study: 15201240
Drug: Age >=
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age >= 65 years, diabetes, previous myocardial infarction, congestive heart failure, use of beta blockers or diuretics at admission, 12 lead ECG ST segment depression at admission, troponin T concentration >= 0.10 microg/l, and >= 1 ST vector magnitude episodes
Study: 15201240
Drug: Age >=
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age >= 65 years, previous myocardial infarction, and troponin T concentration >= 0.10 microg/l
Study: 29356462
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of 99 Tc-MDP
Study: 29356462
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of intravenous drip of 99 Tc-MDP and oral meloxicam tablets
Study: 29356462
Drug: Oral meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral meloxicam tablets
Study: 19804441
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose fluticasone 100 microg/day with intranasal placebo
Study: 19804441
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fluticasone 500 microg/day with intranasal placebo
Study: 19804441
Drug: Combined fluticasone
Normalized name: fluticasone, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined fluticasone 100 microg/day with intranasal fluticasone 200 microg/day
Study: 19804441
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fluticasone vs Low dose fluticasone
Study: 19804441
Drug: Combined vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vs Low dose fluticasone
Study: 8538891
Drug: Verbal medication
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal medication counseling from a pharmacist
Study: 8538891
Drug: No verbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No verbal medication counseling (uncounseled)
Study: 1837743
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg IV before cisplatin, then 1 mg/h for 24 hours; oral 8 mg three times daily on days 2-6) plus Dexamethasone (20 mg IV)
Study: 1837743
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg IV before cisplatin, then 1 mg/h for 24 hours; oral 8 mg three times daily on days 2-6)
Study: 1837743
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Ondansetron + Dexamethasone)
Study: 31311668
Drug: Temelimab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temelimab at doses of 36, 60, 85, and 110 mg/kg
Study: 24171301
Drug: Topical ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ivermectin (1% applied at 400 microg/kg, repeated once the following week)
Study: 24171301
Drug: Permethrin 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 2.5% cream (applied twice at one week intervals)
Study: 21733058
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg (Alo25) added to Metformin and Pioglitazone
Study: 21733058
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg (Met+Pio45)
Study: 16400465
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg loading dose before incision, followed by 1 mg/kg/h for 5 hours)
Study: 16400465
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline bolus and continuous infusion for 5 hours)
Study: 15262026
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with midazolam elixir
Study: 15262026
Drug: Analgesia with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesia with morphine sulphate
Study: 15262026
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with dextromoramide and lorazepam
Study: 2935644
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg diethylstilbestrol orally 3 times daily
Study: 2935644
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oral cyproterone acetate daily
Study: 2935644
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg medroxyprogesterone acetate intramuscularly 3 times weekly for 8 weeks, then 200 mg orally daily
Study: 2935644
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg diethylstilbestrol
Study: 2935644
Drug: 560 mg
Normalized name: spinosad 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 560 mg estramustine phosphate orally for 8 weeks, then 280 mg daily
Study: 30041701
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (POM) supplementation, 50 ml daily for two months